Takeda Pharmaceutical Company Limited, BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, and Attune Pharmaceuticals, Inc., among others, are the key players in the global market for hereditary angioedema therapeutic.
As per the analysis by Expert Market Research, the global hereditary angioedema therapeutic market is estimated to grow in the forecast period of 2022-2027 at a CAGR of 8.7%.
Recurrent episodes of significant swelling are a defining feature of the illness known as hereditary angioedema (angioedema). The limbs, face, digestive system, and airway are the body parts that experience swelling the most frequently. An attack will likely start with a small amount of stress or trauma, but swelling can frequently happen without a clear cause.
The hereditary angioedema therapeutic market growth will likely be fuelled owing to an increase in the knowledge of hereditary angioedema and the expansion of the healthcare sector across emerging economies. Appendicitis, gastrointestinal issues, and other non-allergic angioedema illnesses are sometimes misdiagnosed in hereditary angioedema patients. A significant patient population with severe medical demands is formed by a small number of patients who were incorrectly diagnosed with the illness. In the upcoming years, this is anticipated to be a major market driver for therapeutics for hereditary angioedema.
The growing research and development activities and the investment in orphan drug development will further boost the growth of the hereditary angioedema therapeutic market. Moreover, an increasing attention on the evolving novel therapeutics is expected to further provide potential opportunities for the market growth globally in the upcoming years. The other factors aiding the market growth include rising population and increasing disposable income.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Takeda is a multinational biopharmaceutical company committed to using patient-centred and ethical research and development to improve the health and future of people everywhere. The company has presence in about 80 nations, with the United States and Japan holding the first and third-largest pharmaceutical marketplaces in the world, respectively.
|Headquarters:||North Carolina, United States|
A group of dedicated individuals lead BioCryst Pharmaceuticals, Inc., which works to provide novel treatments for patients with rare diseases. The company has experience in medication research, clinical development, and regulatory affairs. It is involved in developing clinical projects and producing new compounds from its own discovery engine. It focuses on developing medications for rare diseases, where patients' needs are still largely unmet.
|Headquarters:||California, United States|
Ionis Pharmaceuticals, Inc. developed the world's first and only RNA-targeted therapy that is licenced for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. It also has the first and only treatment for children and adults with spinal muscular atrophy. The business's medication discovery platform has provided patients with unmet needs with meaningful solutions.
Pharming Group N.V., a multinational biopharmaceutical business develops precision medicines and novel protein replacement therapies for the treatment of uncommon diseases and unmet medical needs. Recombinant human C1 esterase inhibitor RUCONEST® (conestat alfa), the flagship product of Pharming, has been approved for the treatment of acute attacks of hereditary angioedema (‘HAE’) in individuals in Europe, the United States, Israel, and South Korea. In other regions where it does not yet have marketing authorisation, the product is offered on a named-patient basis.
A biopharmaceutical business called CSL Limited promises to save lives of people who are stricken with chronic medical conditions. The company offers the broadest range of premium plasma-derived and recombinant medications in the market.
|Headquarters:||New York, United States|
Private biotechnology business Attune Pharmaceuticals, Inc. focuses on the development and discovery of new, orally delivered small-molecule medicines for the treatment of rare disorders.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.